Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single and multiple ascending dose study of LEO 153339 in healthy adults
NL-OMON51974Phase 1Active, not recruiting
- Sponsor
- LEO Pharma
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LEO 153339 in psoriasis, sponsored by LEO Pharma. Primary endpoint: Safety and tolerability of LEO 153339. Started May 2021; status: active, not recruiting.
02
Drugs
LEO 153339
03
Conditions
psoriasis
Beyond the preview
Go deeper on NL-OMON51974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51974.